Compare iShares MSCI Japan ETF (EWJ) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs GSK plc — how do they compare? iShares MSCI Japan ETF trades at $97.6 (market cap $23.87B), while GSK plc trades at $46.61 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.8× iShares MSCI Japan ETF's market cap, and GSK plc pays a 3.9% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and GSK plc for 93 Days on average.
| EWJ | GSK | |
|---|---|---|
Market Cap | $23.87B | $91.88B |
Volume | 5,412,820 | 7,730,529 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $61.18 |
52-Week Low | $78.36 | $43.24 |
Typical Hold Time | 56 Days | 93 Days |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.44, down 0.9% on the day amid mixed technical signals. The ETF shows neutral momentum with RSI readings around 50 and faces immediate resistance at $98. Recent news highlights Japan's monetary policy uncertainty as the Bank of Japan navigates rate hikes while facing fiscal challenges and yen volatility.
The outlook remains balanced with international ETF performance showing strength but Japanese equities facing headwinds from rising yields and currency pressures. Key risks include BOJ policy missteps and global bond market volatility, while potential catalysts include sustained international diversification trends and yen stabilization efforts.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
